SINCE the 1980s, researchers have worked tirelessly to develop effective treatments that can suppress the HIV virus to undetectable levels. As a result, by taking a single daily dose of an antiretroviral (ARV) medicine, people with HIV can now expect to live long and healthy lives – as well as prevent transmission to others.
The impact has been dramatic, with annual global AIDS-related deaths having fallen from 2.1 million at the peak in 2004 to 630,000 in 2024. The number of new acquisitions has plummeted too: an estimated 1.3 million people acquired the virus in 2024, marking a 60 per cent decline since the peak in 1995.
“We’re at a pivotal moment in the quest to end the HIV epidemic,” says Jean van Wyk, chief medical officer at ViiV Healthcare. This quest is to meet the UN’s 2030 goals that ViiV has been involved with since the 1980s as the pioneers of the first ARV medicine.







